drugset / Trial / NCT01937806

Phase 3 and Extensional Study of Besifovir

NCT01937806 ↗

Phase 3 Unknown 197 enrolled IlDong Pharmaceutical Co Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

To prove that a study drug is noninferior to a control drug with a proportion of subjects who showed HBV DNA undetected (less than 400 copies/mL (69 IU/mL)) at the 48th week after 48-week administration of Besifovir 150 mg, or Tenofovir 300 mg as a control drug to chronic hepatitis B patients

Timeline

Start
2013-10
Primary completion
2016-02
Completion
2023-01

Outcome

Met primary endpoint

paper 80.9% of patients given BSV and 84.9% of patients given TDF met the efficacy endpoint, indicating the non-inferiority of BSV to TDF. PMID 30448598 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Besifovir Other / unclassified 150 mg Oral
Comparator Tenofovir Small molecule 300 mg Oral